A NEW POSSIBILITY FOR BODY REGULATION?

Experts are increasingly examining retatrutide, a novel medication developed by Eli Lilly, as a potential breakthrough in body loss . Unlike many existing approaches, retatrutide is a twin-action agonist targeting both GLP-1 and GIP, substances that impact appetite and glucose regulation . Early